Company intelligence / Profile preview

ARO Medical

Philadelphia, Pennsylvania, United Statesaromedispa.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s lead candidate, ABX1100, has demonstrated favorable safety and tolerability in phase 1 studies with healthy volunteers, showing approximately a 70% reduction in GYS1 mRNA and protein at ten weeks post-dosing. The drug has advanced to an open-label Phase 1 trial in patients with late-onset Pompe disease. Initial clinical data are expected to be presented in mid-to-late 2024. Preclinical programs are ongoing for autoimmune disorders.

Therapeutic areas: ImmunologyRare Diseases
Modalities: Small interfering RNAProteinSynthetic oligonucleotide
Industry: Biotech

Drug pipeline

1 asset

ARO Cinch

Pre-clinical

Indications: Spinal disc herniation

Partnerships

Johnson & Johnson Innovation – JJDC, Inc.industry collaborations leveraging Centyrins for targeted delivery

Beyond the preview

Go deeper on ARO Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARO Medical.

Explore the full profile